Navigation Links
Genes influence effectiveness of weight-loss drug
Date:9/30/2008

Bethesda, MD (Oct. 1, 2008) Obese patients with a specific genetic make-up lose more weight when taking the weight loss drug sibutramine and undergoing behavioral therapy compared to those without this genetic make-up, reports a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

The obesity epidemic continues to be an increasingly global problem: an estimated 1.6 billion adults worldwide are overweight (body mass index [BMI]>25) and 400 million are obese (BMI>30). In addition, the incidences of diabetes and other debilitating diseases attributable to obesity continue to rise.

While there are numerous options for the treatment of obesity, this study examined sibutramine, a medication approved for the long-term treatment of obesity. The drug creates a feeling of fullness, prevents decline in metabolic rate associated with low calorie diets and causes weight loss, especially when combined with behavioral therapy. However, weight loss with the drug is highly variable. Therefore, a research team at the Mayo Clinic assessed the influence of specific markers of candidate genes controlling serotonergic and adrenergic mechanisms (α2A-receptor, 5-HTTLPR and GNβ3) on weight loss/body composition in response to sibutramine or placebo.

"We found significantly lower values for weight, BMI and proportion of body fat in patients taking sibutramine. The candidate gene variations provided useful markers of enhanced response to the drug," said Michael Camilleri, MD, AGAF, of the Mayo Clinic and lead author of the study. "Gene variations may help select obese patients who are more likely to experience improved outcome with this treatment. Since the different markers were present in almost 50 percent of patients, inclusion of screening for these genetic markers before prescribing the medication may even be cost-effective from a public health perspective."

In this randomized, double-blind, pharmacogenetic study, Dr. Camilleri and colleagues evaluated behavioral therapy and sibutramine (10 or 15 mg daily) or placebo for 12 weeks in 181 overweight or obese participants. They measured body weight, BMI, body composition, gastric emptying and genetic variation.

Study results showed that sibutramine at both doses, given in combination with behavioral therapy, caused significant weight loss (p = 0.009). The drug resulted in lower values for weight, BMI and proportion of body fat compared to placebo (p<0.01, p<0.001 and p=0.05, respectively). Weight loss at four weeks was a predictor of weight loss achieved at 12 weeks.

There was a statistically significant gene-by-dose interaction for GNβ3 genotype. This gene determines the function of G proteins, which are involved in translating the message from surface receptors that bind the transmitters serotonin and norepinephrine (e.g. of cells controlling appetite). Those surface receptors are indirectly influenced by sibutramine, which blocks the reuptake of the two transmitters. For each candidate gene, treatment effects were observed at 12 weeks (p<0.017) for all specific genotype variants. The research showed gene pairs (e.g. for GNβ3and α2A-receptor) resulted in greater sibutramine treatment effects on weight (both p<0.002). However, there was no evidence of synergism between combinations of two genotypes on the response to sibutramine therapy compared to the effect on weight loss associated with individual genotypes.

"Our results suggest the genetic make-up of patients could predispose their responsiveness to a drug. This could have important implications for the future of personalized molecular-based or individualized medicine," added Dr. Camilleri. As new and exciting research like this study continues into the causes, prevention and treatments for obesity, the role played by the GI tract is becoming more defined. This understanding has the potential to lead to novel endoscopic, pharmacological and nutritional therapies for obesity as well as changes in policies and societal practices related to obesity.


'/>"/>

Contact: Alissa Cruz
media@gastro.org
301-272-1603
American Gastroenterological Association
Source:Eurekalert

Related medicine news :

1. Genes affect weight loss drug effectiveness
2. UNC study: Parenting can override effect of genes in how babies respond to stress
3. Type 1 diabetes may result from good genes behaving badly
4. Nanomedical approach targets multiple cancer genes, shrinks tumors more effectively
5. Genesis Pharmaceuticals Received New Purchase Orders Worth $12 Million
6. The first autism disease genes
7. Neurogenesis in the adult brain: The association with stress and depression
8. Beyond PTEN: Alternate genes linked to breast, thyroid and kidney cancer predisposition
9. Researchers Find Genes That Influence West Nile Virus
10. ThermoGenesis Announces 10 New BioArchive(R) System Distributors
11. Genesis Pharmaceuticals Announces New Board Member and Forms Committees
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 19, 2017 , ... ... Thailand presided over the Amazing Thailand Health and Wellness Tourism Showcase 2017 yesterday, ... Noppadon Pakprot, Deputy Governor for Tourism Products and Business at TAT said, “Thailand ...
(Date:8/18/2017)... NY (PRWEB) , ... August 18, 2017 , ... ... of this summer’s edition of “Vision & Hearing,” advocating for active, healthy lifestyles ... focuses on resources available for individuals with hearing impairments and shares the latest ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... asset protection assistance to communities in North-Central West Virginia, is embarking on a ... at-risk boys in the area. , The Chestnut Mountain Ranch (CMR) is a ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... The Golseth ... in the Dallas/Fort Worth area, is spearheading a regional charity campaign organized to provide ... , In early June of this year, Christina and her children returned from out ...
(Date:8/18/2017)... , ... August 18, 2017 , ... Inc. magazine has ... the most prestigious ranking of the nation's fastest-growing private companies. This marks the eighth ... Inc. 5000 ranking . This year’s ranking reflects ASH’s 76 percent overall revenue ...
Breaking Medicine News(10 mins):
(Date:8/3/2017)... , Aug. 3, 2017  Opioid addiction and other ... up healthcare costs and threatening outcomes, were problems taken ... and IVD industry that support them, met this week. ... researcher said that drugs of abuse, procalcitonin and acute ... at the organization,s 69th meeting in San ...
(Date:8/2/2017)... , Aug. 2, 2017  Life Flight Network and ... The agreement improves patient care and operational efficiency for patients ... Springfield , Cottage Grove , and ... medical transportation. PeaceHealth and Life Flight Network work collaboratively to ... during transport, or when a time sensitive emergency exists. ...
(Date:7/31/2017)... Mich. , July 31, 2017  Diplomat Pharmacy, Inc. ... in southeast Michigan by Crain,s ... ranks private and public companies by three-year revenue growth. This ... To view the complete list, visit ... Fast 50 is an incredible triumph," said Phil Hagerman ...
Breaking Medicine Technology: